Trial Profile

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glofitamab (Primary) ; Cyclophosphamide; Doxorubicin; Polatuzumab vedotin; Prednisone; Rituximab
Indications B-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms SKYGLO
Sponsors Roche

03 Apr 2025 Planned End Date changed from 28 Feb 2029 to 31 Dec 2030.
03 Apr 2025 Planned primary completion date changed from 1 Jun 2026 to 31 Dec 2027.
10 Dec 2024 Results presented at the 66th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com